We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-15.5%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$351M
Cap. Flow
+$73.5M
Cap. Flow %
5.83%
Top 10 Hldgs %
73.34%
Holding
36
New
3
Increased
5
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$94.4M
2
XLO icon
Xilio Therapeutics
XLO
+$47.8M
3
MRSN
Mersana Therapeutics
MRSN
+$13.2M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.63M
5
TSVT
2seventy bio
TSVT
+$5.6M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$62.1M
2
AVIR icon
Atea Pharmaceuticals
AVIR
+$18.9M
3
IVVD icon
Invivyd
IVVD
+$14.3M
4
BLUE
bluebird bio
BLUE
+$3.45M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$2.49M

Sector Composition

Rank Sector Weight
1 Healthcare 95.4%
2 Financials 3.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XFOR icon
26
X4 Pharmaceuticals
XFOR
$425M
$6.61M 0.52%
96,218
+25,567
+36% +$3.23M
BLUE
27
DELISTED
bluebird bio
BLUE
$5.38M 0.43%
26,909
-14,638
-35% -$3.45M
ARYE
28
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$4.85M 0.38%
500,000
– –
PANA
29
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.85M 0.38%
500,000
– –
BLSA
30
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.78M 0.38%
487,500
– –
TSVT
31
DELISTED
2seventy bio
TSVT
$4.6M 0.36%
+179,393
New +$5.6M
OMEG
32
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$3.91M 0.31%
400,000
– –
FLACU
33
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$2.98M 0.24%
300,000
– –
JYAC
34
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.93M 0.23%
300,000
– –
MLTX icon
35
MoonLake Immunotherapeutics
MLTX
$1.47B
– –
-250,000
Closed -$2.49M
DRNA
36
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-3,080,237
Closed -$62.1M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q4 2021 Portfolio in Review

As of Q4 2021, Bain Capital Life Sciences Investors held 36 positions worth $1.26B, down 22% from $1.61B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Bain Capital Life Sciences Investors deployed $73.5M of net new capital in Q4 2021, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was EQRx, Inc. Common Stock: 10,003,573 shares worth $68.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Atea Pharmaceuticals, an estimated $18.9M trimmed.

  • Bain Capital Life Sciences Investors's largest Q4 2021 buy was EQRx, Inc. Common Stock: 10,003,573 shares worth $68.2M.
  • Bain Capital Life Sciences Investors added most to Mersana Therapeutics in Q4 2021, an estimated $13.2M increase.
  • Bain Capital Life Sciences Investors's biggest Q4 2021 reduction was Atea Pharmaceuticals, cutting an estimated $18.9M.
  • Bain Capital Life Sciences Investors fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $62.1M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 73% of its $1.26B portfolio in Q4 2021.
  • Bain Capital Life Sciences Investors opened 3 new positions and closed 2 in Q4 2021.
  • Bain Capital Life Sciences Investors's portfolio value fell 22% quarter-over-quarter to $1.26B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2021, filed 14 Feb 2022.